Interpace Biosciences, Inc. IDXG
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.13M | 9.03M | 9.22M | 8.76M | 9.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.13M | 9.03M | 9.22M | 8.76M | 9.23M |
| Cost of Revenue | 3.48M | 3.13M | 3.18M | 3.32M | 3.96M |
| Gross Profit | 5.65M | 5.90M | 6.04M | 5.44M | 5.28M |
| SG&A Expenses | 5.18M | 4.63M | 3.63M | 4.14M | 5.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.81M | 7.91M | 6.95M | 7.61M | 9.18M |
| Operating Income | 321.00K | 1.12M | 2.28M | 1.15M | 56.00K |
| Income Before Tax | 330.00K | 1.13M | 1.54M | 1.00M | -533.00K |
| Income Tax Expenses | 64.00K | 302.00K | -21.22M | -11.00K | -- |
| Earnings from Continuing Operations | 266.00K | 831.00K | 22.75M | 1.01M | -533.00K |
| Earnings from Discontinued Operations | -108.00K | -110.00K | -95.00K | -100.00K | -107.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 158.00K | 721.00K | 22.66M | 911.00K | -640.00K |
| EBIT | 321.00K | 1.12M | 2.28M | 1.15M | 56.00K |
| EBITDA | 448.00K | 1.24M | 2.40M | 1.26M | 157.00K |
| EPS Basic | 0.03 | 0.16 | 25.58 | 1.03 | -0.72 |
| Normalized Basic EPS | 0.04 | 0.16 | 1.58 | 0.71 | -0.01 |
| EPS Diluted | 0.03 | 0.13 | 4.08 | 0.18 | -0.72 |
| Normalized Diluted EPS | 0.04 | 0.13 | 0.25 | 0.11 | -0.01 |
| Average Basic Shares Outstanding | 5.54M | 4.56M | 885.80K | 885.00K | 884.60K |
| Average Diluted Shares Outstanding | 5.54M | 5.54M | 5.54M | 5.54M | 884.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |